Zimmer Biomet Holdings Earnings Call Transcripts
Fiscal Year 2026
-
A major U.S. sales channel overhaul is underway, aiming for full transition by end-2027 and improved productivity. Recent product launches and acquisitions are driving growth, while innovation and robotics remain key priorities. Financially, 2026 is a transition year, with mid-single-digit growth targeted beyond.
-
The meeting highlighted ongoing transformation, strategic focus on innovation, and operational excellence. Shareholders approved all board proposals except the independent chairman request, while management emphasized capital return, U.S. sales improvement, and S.E.T. growth.
-
Q1 2026 delivered strong revenue growth at the top of guidance, with robust U.S. and technology performance. New product launches, especially in Japan, and ongoing sales force transformation are driving future growth. Integration of recent acquisitions and a $1B buyback support a balanced capital strategy.
-
Sales and EPS exceeded expectations, driven by strong technology adoption and new product launches, with guidance for EPS and free cash flow raised for 2026. Strategic investments and sales force transformation are progressing, while recent acquisitions accelerate growth.
-
The event highlighted a five-year transformation with strong growth, a shift to customer-centric innovation, and a major overhaul of the U.S. sales model. Key product launches and investments in robotics and ASCs are set to drive future growth, with tempered 2026 guidance reflecting ongoing transformation.
Fiscal Year 2025
-
Q4 2025 saw 5.4% organic sales growth and strong U.S. performance, with new products and robotics driving results. 2026 guidance anticipates 1%-3% revenue growth and continued Salesforce transformation, with short-term disruption but long-term productivity gains expected.
-
Healthy orthopedic markets and robust innovation are driving growth, with new technologies like anti-infective implants and autonomous robotics set for launch in 2026-2027. Operational improvements and a focus on U.S. performance are expected to support margin expansion and consistent execution.
-
Q3 2025 saw 5% organic sales growth, led by strong U.S. performance and new product adoption, though late-quarter international and non-core segment weakness impacted results. Guidance for 2025 was revised slightly lower, but EPS and cash flow targets remain intact, with continued focus on innovation and operational improvements.
-
Earnings guidance was raised on the back of lower tariffs, strong cash flow, and operational improvements. New product launches and ASC expansion are driving growth, with further acceleration expected in 2026. The company is transforming through innovation, strategic acquisitions, and a focus on specialization and culture.
-
Q2 2025 saw 2.8% organic sales growth, strong U.S. hip and SET segment performance, and raised full-year guidance for revenue and EPS. Strategic acquisitions, including Monogram Technologies and Paragon 28, are expected to drive future growth and innovation.
-
2025 guidance remains strong, with 3%-5% organic growth expected and new products driving momentum, especially in the second half. Paragon 28 integration is progressing well, supporting both ASC expansion and future M&A. Tariff impacts are conservatively estimated, with potential upside from regulatory developments.
-
Q1 2025 saw 2.3% constant currency sales growth, strong U.S. Hips and S.E.T. performance, and successful Paragon 28 integration. 2025 guidance reaffirms 3%-5% organic growth, with tariffs offset by FX and operational levers. New product launches and ASC expansion are key growth drivers.
-
Orthopedic market growth is stable at 4-5%, supported by demographic trends, ASC expansion, and technology advances. New product launches and the Paragon 28 acquisition are set to drive above-market growth, with strong margin expansion and a focus on integrating recent deals before pursuing further M&A.
-
A robust innovation cycle is driving new product launches across hips, knees, and robotics, with operational challenges resolved and a focus on mid-single-digit revenue growth, margin expansion, and strong free cash flow. ASC growth, pricing improvements, and strategic M&A are key priorities for 2025. New leadership and a direct-to-patient campaign support a bold long-term vision.
Fiscal Year 2024
-
Q4 2024 saw nearly 5% constant currency sales growth, with strong S.E.T. and international performance. 2025 guidance anticipates 3%-5% constant currency revenue growth and $8.15-$8.35 adjusted EPS, with Paragon 28 acquisition expected to accelerate growth and diversification.
-
Key priorities include operational excellence, innovation, and a robust product pipeline, with 50 launches planned over three years. Market growth is driven by demographics, technology, and positive pricing, while operational and commercial execution improvements are targeted for 2025. New product launches and AI-driven solutions are expected to accelerate growth and market share recovery.
-
Management detailed a strategic transformation, consistent financial growth, and robust innovation pipeline, with durable market trends supporting 4%-6% top-line growth through 2027. ASC leadership, margin expansion, and improved pricing discipline underpin confidence in future performance.
-
Q3 2024 saw over 4% sales growth and strong EPS, despite ERP-related headwinds now largely resolved. Innovation and new product launches drove momentum in knees, hips, and SET, with updated 2024 guidance reflecting currency and operational factors.
-
Recent ERP migration caused operational disruptions, mainly in the U.S. and Canada, with up to 1% sales impact expected in 2024, but robust growth continues in key segments. Product innovation, ASC expansion, and a strong financial strategy underpin confidence in multi-year growth.
-
Consistent mid-single-digit growth and innovation leadership continue, with 50 new products planned. A recent ERP transition caused a temporary 1% revenue impact, mainly in the U.S. and Canada, but remediation is underway and long-term growth targets remain intact.
-
Q2 2024 delivered 5.6% constant currency revenue growth and 10% adjusted EPS growth, driven by strong international and enabling technology performance. Guidance for 2024 is reaffirmed despite FX headwinds, with continued investment in innovation and operational excellence.
-
Management outlined a strategic transformation focused on innovation, portfolio diversification, and disciplined M&A to drive growth above 4% WAMGR, targeting 5%. Robotics and cementless knee penetration are set to double by 2027, with multiple new product launches and operational efficiencies supporting margin expansion.